Diane C. Young - Nov 12, 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP, Chief Medical Officer
Signature
/s/ Sam Martin, attorney-in-fact for Diane C. Young
Stock symbol
CLDX
Transactions as of
Nov 12, 2021
Transactions value $
-$149,781
Form type
4
Date filed
11/16/2021, 03:02 PM
Previous filing
Jun 21, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $47.7K +4.6K +217.49% $10.38 6.72K Nov 12, 2021 Direct
transaction CLDX Common Stock Sale -$198K -4.6K -68.5% $42.94 2.12K Nov 12, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -4.6K -6.39% $0.00 67.4K Nov 12, 2021 Common Stock 4.6K $10.38 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6400 to $43.2000 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.